National Health Law Program Comments on HHS Plan to Lower Drug Prices

Executive Summary

The Department of Health and Human Services (HHS) published a Request for Information seeking comments on its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. National Health Law Program’s response, filed July 16 focuses on three key areas that the HHS Blueprint addresses only in part, or overlooks completely: pricing and access to outpatient prescription drugs in Medicaid; proposals to reduce consumer cost sharing in the private insurance market; and strategies to reduce drug prices. National Health Law Program urges HHS to reject cost-saving measures that would cut Medicaid enrollee access to outpatient prescription drugs. National Health Law Program also outlines steps HHS can take to lower consumer out-of-pocket expenses, such as barring the use of co-insurance whereby insurers require consumers to pay a percentage of the costs for prescription drugs, which unduly burdens those with serious or chronic medical conditions. And National Health Law Program’s comments describe a number of measures to curb pharmaceutical company profiteering on the backs of health care consumers and tax payers. These include using federal “march in” rights to make sole-source drugs more available, like Truvada, used as Pre-Exposure Prophylaxis (PrEP) to prevent HIV infection.

Related Content

For almost 50 years, the National Health Law Program has fought to expand access to quality health care to low-income individuals and underserved communities. Today we are pleased to launch a newly designed website for our future work to make health care a reality for all people. Please take time to peruse our new site, and sign up for our email updates to learn about us, watch the work we do, and become engaged.

Continue to site